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With the increasing emphasis on photocoagu-
lation therapy in diabetic retinopathy, its potentials 
and, most probably, the beneficial effects such ther-
apeutic modality may have in arresting or even 
improving diabetic retinopathy, one should realize 
the limitations, the present lack of factual knowl-
edge, and the theories underlying such treatment. 
One should also keep in mind that light-includ-
ing laser-coagulation of the retina is still employed 
selectively in quite a number of other pathological 
fundus conditions with time-proven effectiveness 
though it no longer receives the same wide general 
attention that its use in diabetic retinopathy re-
ceives today. Other ocular conditions exist, how-
ever, where investigators and practitioners in the 
field of ophthalmology differ strongly in their opin-
ions as to the efficacy of this therapeutic tool, and 
even to the advisability of its use, for example, 
chorioretinal malignant tumors. 
Much overemphasis has been placed on the use 
of laser in clinical retinal photocoagulation over the 
already established "white light source," a high pres-
sure Xenon arc lamp, as employed in the Zeiss 
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Photocoagulator. However, the latter is as useful to-
day as it has been for over a decade prior to the 
invention of lasers. Of the many hundreds of laser 
sources now developed, only the solid state pulsed 
Ruby laser and the Argon gas laser-either with a 
continuous wave (CW) or in a pulsed operation-
have, as of now, found wide utilization in clinical 
ophthalmology. Their use, sometimes in combina-
tion with the "white light" coagulator, add to our 
therapeutic armamentarium in certain clinical situ-
ations. 
Figure 1 shows diagrammatically the spectral 
emission of the Xenon arc coagulator and the nar-
row band emissions within the visible, near ultra-
violet (UV) and near infrared (IR) ranges of 
various lasers which are primarily of ophthalmo-
logical interest. Of those, the Ruby laser light is of a 
deep red color (.\. 694.3 nm), and the Argon laser 
has several bands of spectral emission primarily in 
the blue-green region (A. 485-515 nm). Figure 2 
presents the absorption characteristics of the retinal 
pigment epithelium and choroid for light of equal 
intensity and incident on the cornea. 
The Ruby laser, usually operated in a single 
pulse mode in the microsecond range, and the 
variable retinal image diameter of the laser beam 
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Fig. I-Spectral position of light emitted from various laser 
sources in comparison with emission characteristics of a 
Xeqon high-pressure light source. 
of about 100-500 µ have proven to be of particular 
value in the treatment of small lesions close to the 
macula. The dark red color of the emitted laser 
beam allows for treatment without retrobulbar 
anesthesia, since in this spectral range no photo-
phobia is elicited, and the eye has "no time to move" 
during the short exposure time. On the other hand, 
light of this wavelength is greatly reflected by the 
red blood vessels and only minimally absorbed by 
them, which makes it less usable for coagulation of 
vascular lesions. If those are located within the 
retina, the heat generated by absorption of the light 
in the retinal pigment epithelium may secondarily 
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Fig. 2-Percent absorption in human retinal pigment epithe-
lium and choroid for equal intensities and light incident on 
the cornea. Ar = Main Argon laser emission bands. R = 
Ruby laser wavelength. 
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cause vessel obliteration. In cases where vessel pro-
liferation into the vitreous has developed, as seen 
primarily in diabetic retinopathy (fig. 3) am?ng 
other pathological conditions, the Ruby laser hght 
is relatively ineffective and may even be hazardous 
if the light energy is increased to achieve coagul.a-
tion of vascular structures within the vitreous it-
self (7). This is the area where the Argon laser 
has found its principal and dominant role in clin-
ical ophthalmology. The bright bluish-green laser 
beam produces photophobia similar to white light 
and, thus, in most situations retrobulbar ')nesthe-
sia is required . This spectral wavelength is strongly 
absorbed by the hemoglobin and achieves coagula-
tion of the blood with vascular obliteration most 
easily and successfully ( 6, 9). . 
In early stages of diabetic retinopathy with 
retinal microaneurysms, hemorrhages, and exudates 
(figs. 4 and 5) , and in more advanced stages where 
neovascularization has already developed (fig. 6), 
both white light and Argon laser light are equally 
effective. Only in conditions where the lesiJns are 
close to the macula is the Argon laser superior since 
its greater light intensity permits retinal coagulation 
of very small foci, thus creating a condition of less 
potential danger to the macula and fovea. 
More recently, Blair and Gass (2) showed that 
"mild photocoagulation" in the area of the maculo-
papillar bundle did not produce large central scoto-
mata due to destruction of nerve fibers passing over 
the coagulated site to the optic nerve. This obser-
vation had been described in animal experimentation 
using histological techniques at various time inter-
vals following light exposure (7), and in human 
volunteers whose eyes had to be enucleated for 
other pathological reasons ( 8). 
The effectiveness of photocoagulation in dia-
betic retinopathy has not been statistically estab-
lished on a large scale. Its evaluation is difficult 
since the natural pathological condition may fre-
quently undergo periods of arrested states or even 
improvement. It is, therefore, not astonishing that 
a number of ophthalmologists are not in favor of 
this relatively destructive form of therapy. Pro-
ponents for photocoagulation therapy can be largely 
separated into two groups, that is, 1) those who 
prefer to coagulate only those lesions which may 
potentially cause vitreous hemorrhages and areas of 
neovascularization; and 2) those who want to ther-
apeutically produce large chorioretinal scars in-
volving areas of diseased and ophthalmoscopically 
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Fig. 3a-Massive vascular proliferation. 
Fig. 3b-Glial and vascular proliferation. 
normal-appearing retinal tissue as well. The latter 
concept is based on certain naturally occurring patho-
logical processes involving the eye which have 
seemingly prevented the development of diabetic 
retinopathy or at least have retarded its progression 
to a significant degree. 
Such conditions have been described in eyes 
with severe glaucomatous optic atrophy, severe 
myopia, conditions with decreased retinal arterial 
blood supply, retinitis pigmentosa, large chorioretinal 
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Fig. 3c-Moderate glial proliferation. 
Fig. 3d-Extensive glial proliferation. 
scars following inflammatory reactions, and so forth. 
In many of the latter instances, the disease was 
present unilaterally with the fellow eye serving as a 
control. Hence, production of similar large chorio-
retinal scars with photocoagulation was expected to 
create a similar arrest of the progressing stages of 
diabetic retinopathy by way of reducing retinal blood 
supply as is common in all of the above mentioned 
disease entities. 
However, regardless of whether one follows 
292 
Fig. 4-Retinal hemorrhages, few exudates, and micro-
aneurysms. 
Fig. 5-Hard exudates with some new vessel formation at 
the optic disc. 
the more conservative and restricted application, 
as we do, or the more aggressive approach, photo-
coagulation therapy of diabetic retinopathy seems 
presently to be the most effective of all therapeutic 
attempts to bring this disease process under con-
trol. It is at the same time considered relatively safe 
as measured by experiences and data collected over 
the last 10 years with many hundreds of patients 
treated in this fashion. Also, in contrast to the 
surgical approach of pituitary ablation, the general 
state of the diabetic patient is not affected by photo-
coagulation. Pituitary ablation was amenable only 
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to patients who had no other organs involved to 
any measurable extent, one eye having already be-
come practically blind with the fellow eye still having 
useful visual acuity, and where the patients' back-
ground allowed for a continuous controlled medical 
substitute therapy throughout the remainder of their 
lives. 
As to the prognosis of photocoagulation therapy, 
it is generally believed that its greatest beneficial 
results can be expected if treatment is provided in 
the early stages of the retinopathy before vaso-
proliferation takes place. In many cases of macular 
edema with reduced vision and in cases of extensive 
retinal exudates, flucirescein angiography allows 
visualization of vascular leakage which can then be 
effectively sealed off by coagulation treatment. How-
ever, this appears not to be the only mechanism 
involved in the further prevention of retinal edema. 
Peyman and Bok ( 12) have shown in peroxidase 
diffusion studies in the normal and laser-coagulated 
retina of primate retinae that the normal barrier at 
the site of tight junctions of the pigment epithelium 
broke down at the site of the coagulation. This al-
lowed intercellular peroxidase diffusion to take 
place across the original junctional barrier in both 
directions, that is, from the choriocapillaries to the 
retina and vice versa. However, diffusion in the 
retina-to-choroid direction was more extensive than 
chorioretinal diffusion. The investigators concluded 
from these observations that the breakdown of the 
junctional complexes of the retinal pigment epithe-
lium in addition to the alterations in the permeability 
of the choriocapillaries account for the disappear-
ance · of sub- and intraretinal fluid after photo-
coagulation treatment. 
Severe vascular proliferation treated with the 
Argon laser is at present still experimental and its 
lasting effect is still questionable. However, in those 
conditions with extremely poor visual prognosis, 
photocoagulation as well as the more recent sur-
gical attempts ( 1) seem to be warranted. 
It should, again, be re-emphasized that light 
coagulation therapy in diabetic retinopathy is still 
debated as to its efficacy. If effective, it appears that 
treatment of early stages is more amenable and the 
response more successful. This possible success is 
somewhat interfered with by the delay in which the 
patient is referred for coagulation treatment. This 
understandable hesitation in subjecting the patient to 
a not firmly established certain form of therapy may 
lead on the other hand to more severe grades of the 
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retinopathy which are much more questionable in 
their response to photocoagulation. 
Other therapeutic approaches using hormones, 
vitamins, anticoagulants, calcium, aminoacids, lip-
otropic substances, arttimetabolites, and so forth, 
have not provided a controlling effect on the progres-
sion of diabetic retinopathy. Recently, attention has 
again been focused on the possible beneficial action 
of salicylic acid on the development and progression 
of this retinal pathology. Carroll and Geeraets ( 3) 
reported clinical observations based on diabetic pa-
tients on long-term salicylic acid intake vs. those 
without or with only occasional intake of this 
medication. Their statistical evaluation seemed to 
prove a significantly lower grade of retinopathy in 
the former. Findings of Dobbie et al. ( 4) seem to 
support this. They advanced the theory by which 
salicylates interact with the progression of the ret-
inopathy by the prevention of platelet coagulation 
due to an abnormal aggregation-enhancing plasma 
factor in diabetes. Such relatively simple chemo-
therapy should, therefore, be more closely ex-
amined as to its effectiveness under controlled con-
ditions and in a relatively large patient population. 
In the apparently effective low dose in which sali-
cylates would have to be prescribed, other side ef-
fects, that is, gastrointestinal hemorrhages, would not 
be expected. Caution would, however, be indicated 
in hepatic disease, hypoprothrombinemia, hemo-
philia, vitamin K deficiency, and other hemorrhagic 
diseases in association with diabetes. However, con-
trolled studies of drugs in humans have been almost 
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Fig. 6-(Top left) Fine exudates, retinal hemorrhages, and 
early neovascularization; (Top and bottom right) Early 
vasoproliferation with neovascularization, hemorrhages, and 
fine exudates. 
impossible because of the random occurrence, ran-
dom progression, and irregular and unpredictable 
incidence of spontaneous remissions. 
In recent years many authors have stressed that 
therapy in diabetic retinopathy cannot be success-
fully accomplished until adequate experimental ani-
mal models have been produced to study the var-
ious ramifications of the disease, including controlled 
drug studies. Although diabetic retinopathy in 
animals has been successfully produced ( 5), these 
294 
time consuming and very costly experiments have 
left the question unanswered as to the similarity of 
the pathogenesis of the retinopathy and, hence, 
whether it is comparable to human diabetic reti-
nopathy. Heath ( 10) reported a literature review on 
this topic in 1970. 
In previous efforts to study diabetic retinopathy 
in experimental animals, only two forms have been 
available: 1) animals with spontaneous diabetes 
which were kept alive and were bred for further 
observation, progression of the disease and its ocular 
complications, and its genetic implications in produc-
ing the disease in the offspring; 2) animals which were 
made artificially diabetic with alloxan or growth 
hormone, and their clinical status was followed 
under strict observation for possible development of 
diabetic retinopathy. The only variation in these 
two basic approaches has been to vary the degree 
of diabetic control. 
Several important metabolic characteristics of 
retinas in human and animal diabetics have been 
ascertained in recent years: 
1) increased lactate levels 
2) increased C02 levels 
3) increased glucose levels (higher than in the 
general circulation and insulin resistant) 
4) increased lactic dehydrogenase activity 
That the increased lactate level may be a 
direct stimulant to abnormal vascular changes was 
suggested by Imre's work ( 11) in which he produced 
intravitreal neovascularization in the eyes of kittens 
by injecting 0.1 % lactic acid into the vitreous 
body. 
In addition to the abnormal metabolic pro-
cesses in diabetic retinas and the premise that these 
may produce the abnormal vascular changes, it is 
also now under consideration whether abnormal 
antigen-antibody reactions may be one of the etio-
logic factors in initiating the vascular changes. The 
insulin inhibitor may be the antigen in this abnor-
mal immunological response, and increased capil-
lary permeability caused by this reaction may be the 
initial process in the vascular changes. Abnormal 
metabolites might also act as antigens. 
In addition to the present knowledge about 
the metabolic abnormalities in diabetic retinopathy, 
there is also some evidence about the changes oc-
curring in retinitis pigmentosa which apparently 
prevent the development of diabetic retinopathy. 
In this disease, taurine is reduced in amount; ~-
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aminoisobutyric acid is reduced in concentration ; 
and there is a reduction in anaerobic glycolysis 
which can be reversed by giving pyruvate. One 
could speculate that by increasing these factors, 
diabetic retinopathy could be enhanced as well. 
With this increasing knowledge of the path-
ological state of the retinal biochemistry, new che-
motherapeutic agents may be developed and in-
vestigated. 
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